ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 130

Is Bone Scintigraphy Still Useful to Diagnose Rheumatoid Arthritis After the Appearance of 2010 ACR/EULAR Classification Criteria?

Ji Young Kim1, Soo-Kyung Cho2, Min-Kyung Han2, Yun Young Choi1 and Yoon-Kyoung Sung2, 1Department of Nuclear Medicine, Hanyang University College of Medicine, Seoul, South Korea, 2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: diagnostic criteria and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Ultrasound, Nuclear Medicine and Fluorescence Imaging

Session Type: Abstract Submissions (ACR)

Background/Purpose: For many years, the importance of bone scintigraphy to measure inflammation in the joints of patients with RA has been emphasized. Moreover, increased blood pool activity of involved joints in bone scintigraphy corresponds to inflammatory synovitis which is characteristic feature in early RA. Therefore, bone scintigraphy especially with blood pool phase, might be useful in suggesting early joint involvement in RA. The aim of this study was to investigate the usefulness of bone scintigraphy in the diagnosis of rheumatoid arthritis (RA) with assisting the 2010 ACR/EULAR classification criteria.

Methods: A total of 156 patients who firstly visited the rheumatology department and had taken bone scintigraphy and blood pool image with screening laboratory and radiologic tests to confirm RA diagnosis were retrospectively enrolled. Gold standard RA patients were defined as the patients who started disease modifying anti-rheumatic drugs within 3 months of their first visit. After dividing patients into two groups according to the presence or absence of arthritis on their first presentation, we evaluated the diagnostic validity of bone scintigraphy as an independent diagnostic tool (BS only) and as an assistant tool for physicians’ application of 1987 and 2010 criteria (BS assisted diagnosis) to detect RA. In BS assisted diagnosis, the number, symmetricity, and distribution of involved joints were evaluated with BS results instead of physician’s assessment.    

Results: Seventy-five (48.1%) of the 156 patients had active arthritis on physical examination (Group I) and the others of 81 patients did not have arthritis at first visit (Group II). Among them, 56 (74.7%) in group I and 5 (6.2%) in group II were RA patients, respectively. For group I patients (n=75), who were eligible to 2010 criteria, the sensitivity of the bone scintigraphy alone was extremely low (42.9%) with elevated specificity (100%), though those of 2010 criteria assessed by only physician (82.1% and 94.7%, respectively). For this group, the sensitivity of BS assisted diagnosis (75.0%) was slightly lower than that of the diagnosis by physician. For group II patients (n=81) who are not eligible for 2010 criteria, only BS or BS assisted diagnosis identified 2 more RA patients among 5 gold standard RA patients who did not satisfy either 1987 or 2010 criteria (Table).

Conclusion: In usual practice, BS assisted diagnosis is not superior to physician’s assessment, especially after appearance of 2010 ACR/EULAR classification criteria. However, bone scintigraphy is still helpful to rule out non RA patients in patients with arthritis and to find out RA patients among patients without arthritis on physical examination.

Table. Comparison of the diagnostic validities of the bone scintigraphy (BS) and BS assisted diagnosis

 

Subjects

Sensitivity, %

Specificity, %

PPV, %

 NPV, %

AUC (95% CI)

Group I. Patients with Arthritis at presentation (who eligible for 2010 criteria, n=75)

 

 

BS only

42.9

100

100

37.3

–

1987 criteria

Physician only

66.0

99.2

97.4

86.1

0.864(0.770-0.958)

Physician with BS               

58.9

100

100

45.2

0.911(0.844-0.977)

   2010 criteria

Physician only

82.1

94.7

97.9

64.3

0.923(0.803-1.0)

Physician with BS               

75.0

94.7

97.7

56.2

0.943(0.883-1.0)

Group II. Patients without Arthritis at presentation (who are not eligible for 2010 criteria, n=81)

 

 

BS only

40.0

98.7

66.7

96.2

–

1987 criteria

Physician only

0

100

–

93.8

0.636 (0.362-0.909)

Physician with BS

20.0

100

100

95.0

0.696 (0.355-1.0)

   2010 criteria

Physician only

0

100

–

93.8

0.861 (0-1.0)

Physician with BS

40.0

100

100

96.2

0.862 (0 -1.0)


Disclosure:

J. Y. Kim,
None;

S. K. Cho,
None;

M. K. Han,
None;

Y. Y. Choi,
None;

Y. K. Sung,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-bone-scintigraphy-still-useful-to-diagnose-rheumatoid-arthritis-after-the-appearance-of-2010-acreular-classification-criteria/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology